

FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

- 1) **How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies:**

•	Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	52
•	Abemaciclib + Fulvestrant	1
•	Alpelisib + Fulvestrant	2
•	Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide only	18
•	Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide + Paclitaxel	4
•	Atezolizumab	13
•	Capivasertib	1
•	Capecitabine as a single agent	54
•	Carboplatin + Paclitaxel	76
•	Elacestrant	2
•	Eribulin as a single agent or in combination	31
•	Everolimus + Exemestane	0
•	Fulvestrant as a single agent	0
•	Palbociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	25
•	Palbociclib + Fulvestrant	5
•	Parp Inhibitors (Olaparib/Talazoparib)	5
•	Pembrolizumab Monotherapy	52
•	Pembrolizumab + Anthracycline (e.g. doxorubicin or epirubicin) + Cyclophosphamide	7
•	Carboplatin + Paclitaxel + Pembrolizumab	8
•	Pertuzumab (Perteja) + Trastuzumab (Herceptin)	1
•	Phesgo (Pertuzumab + Trastuzumab in a single injection)	46

•	Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	61
•	Ribociclib + Fulvestrant	24
•	Sacituzumab Govitecan	4
•	Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent	15
•	Trastuzumab deruxtecan (Enhertu)	3
•	Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel	52
•	Trastuzumab emtansine (Kadcyla)	12
•	Any other active systemic anti-cancer therapy	2

- 2) In the past 3 months, how many patients have been treated with the following systemic anti-cancer therapies for breast cancer (please indicate whether they were treated for early or metastatic disease):

	Total Patients	Early Patients	Metastatic Patients
Phesgo (Pertuzumab + Trastuzumab in a single injection)	46	14	32
Pertuzumab (Perteja) + Trastuzumab (Herceptin)	1	0	1
Trastuzumab (Herceptin) as a single agent or in combination with Paclitaxel	52	26	26
Trastuzumab deruxtecan (Enhertu)	3	0	3
Trastuzumab emtansine (Kadcyla)	12	5	7
Abemaciclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	52	47	5
Abemaciclib + Fulvestrant	1	1	0
Ribociclib + Aromatase Inhibitor (e.g. anastrozole, exemestane, letrozole)	61	61	0
Ribociclib + Fulvestrant	24	24	0
Capecitabine as a single agent	54	24	30
Carboplatin + Paclitaxel	76	16	60
Carboplatin + Paclitaxel + Pembrolizumab	8	7	1

- 3) Does your trust participate in any clinical trials for breast cancer? If so, please provide the name of each trial, and the number of patients taking part.

The Trust currently has one breast cancer trial open to recruitment:

'Understanding Side Effects Experienced By Women Prescribed Hormone Therapy (SWITCH)'.

37 patients recruited in total.

(Women on adjuvant hormone therapy are often 'switched' between different brands of the drug depending on which one the pharmacy is stocking at the time. Although the different generic brands will have the same active ingredient, assured through quality assurance processes, there may be differences in excipients (other chemical agents added to make the tablet) across brands, leading to women reacting differently to different brands.)

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, you have the right to request an internal review. Please write to the Freedom of Information Department (esh-tr.foi@nhs.net), quoting the above reference, within 40 working days. The Trust is not obliged to accept an internal review after this date.

Should you still be dissatisfied with your FOI request, you have the right of complaint to the Information Commissioner at the following address:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire SK9 5AF

Telephone: 0303 123 1113

Yours sincerely

Freedom of Information Department
esh-tr.foi@nhs.net